IRWD vs. INVA, OPK, EBS, RIGL, CDXS, XOMA, VSTM, VNDA, SGMO, and LXRX
Should you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include Innoviva (INVA), OPKO Health (OPK), Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Codexis (CDXS), XOMA (XOMA), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Sangamo Therapeutics (SGMO), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "biotechnology" industry.
Ironwood Pharmaceuticals vs.
Innoviva (NASDAQ:INVA) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.
99.1% of Innoviva shares are owned by institutional investors. 1.7% of Innoviva shares are owned by company insiders. Comparatively, 12.9% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Ironwood Pharmaceuticals received 211 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 61.17% of users gave Ironwood Pharmaceuticals an outperform vote while only 57.55% of users gave Innoviva an outperform vote.
Innoviva has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Innoviva has a net margin of 18.31% compared to Ironwood Pharmaceuticals' net margin of -0.65%. Innoviva's return on equity of 20.84% beat Ironwood Pharmaceuticals' return on equity.
In the previous week, Ironwood Pharmaceuticals had 11 more articles in the media than Innoviva. MarketBeat recorded 15 mentions for Ironwood Pharmaceuticals and 4 mentions for Innoviva. Innoviva's average media sentiment score of 1.05 beat Ironwood Pharmaceuticals' score of 0.31 indicating that Innoviva is being referred to more favorably in the media.
Ironwood Pharmaceuticals has a consensus target price of $8.60, suggesting a potential upside of 368.41%. Given Ironwood Pharmaceuticals' higher probable upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Innoviva.
Innoviva has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.
Summary
Innoviva beats Ironwood Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Ironwood Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ironwood Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:IRWD) was last updated on 2/21/2025 by MarketBeat.com Staff
Free IRWD Stock Alerts